Skip to main content
. 2016 Mar 15;114(6):650–658. doi: 10.1038/bjc.2016.25

Figure 4.

Figure 4

Dose–response curves with novel PI3K-Akt-mTOR inhibitors in BON-1/R and long-term vehicle-treated BON-1 and QGP-1/R and long-term vehicle-treated QGP-1. Cells were treated during 7 days with, respectively, AZD2014 (A, B), OSI-027 (C, D) and NVP-BEZ235 (E, F). Response is expressed as the percentage of vehicle-treated control (±s.e.m.). Control is normalised at 100%.